

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 38

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 38

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 38

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

MODIFICATION

This is to inform you that WHO will henceforth publish lists of recommended INNs **twice a year**.

This new measure is intended to provide information as soon as possible on the names that have reached the status of recommended INNs.

MODIFICATION

L'OMS publiera désormais les listes des DCI recommandées **deux fois par an**.

Cette nouvelle mesure est destinée à informer les lecteurs dès que possible au sujet des dénominations ayant atteint le statut de DCI recommandée.

MODIFICACION

De ahora en adelante, la OMS publicará **dos veces por año** las listas de DCI recomendadas.

Con esta nueva medida se quiere facilitar lo antes posible la información sobre las denominaciones a las que se ha asignado la condición de DCI recomendadas.

Latin, English, French, Spanish:*Recommended INN**Chemical name or description; Molecular formula; Graphic formula**DCI Recommandée**Nom chimique ou description; Formule brute; Formule développée**DCI Recomendada**Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada***abacavirum**


abacavir

(1*S*,4*R*)-4-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]-2-cyclopentene-1-methanol

abacavir

[(1*S*,4*R*)-4-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]cyclopent-2-ényl]méthanol

abacavir

(1*S*,4*R*)-4-[2-amino-6-(ciclopropilamino)-9*H*-purin-9-il]-2-ciclopenteno-1-metanolC₁₄H₁₈N₆O**almotriptanum**

almotriptan


1-[[[3-[2-(dimethylamino)ethyl]indol-5-yl]methyl]sulfonyl]pyrrolidine

almotriptan

1-[[[3-[2-(diméthylamino)éthyl]-1*H*-indol-5-yl]méthyl]sulfonyl]pyrrolidine

almotriptán

1-[[[3-[2-(dimetilamino)etil]indol-5-il]metil]sulfonil]pirrolidina

C₁₇H₂₅N₃O₂S

amlintidum

amlintide

L-lysyl-L-cysteinyl-L-asparaginyll-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyll-L-arginyl-L-leucyl-L-alanyl-L-asparaginyll-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyll-L-asparaginyll-L-phenylalanylglycyl-L-alanyl-L-isoleucyl-L-leucyl-L-seryl-L-seryl-L-threonyl-L-asparaginyll-L-valylglycyl-L-seryl-L-asparaginyll-L-threonyl-L-tyrosinamide, cyclic(2→7)-disulfide

amlintide

(2→7)-disulfure cyclique de L-lysyl-L-cystéinyl-L-asparaginyll-L-thréonyl-L-alanyl-L-thréonyl-L-cystéinyl-L-alanyl-L-thréonyl-L-glutaminyll-L-arginyl-L-leucyl-L-alanyl-L-asparaginyll-L-phénylalanyl-L-leucyl-L-valyl-L-histidyl-L-séryl-L-séryl-L-asparaginyll-L-asparaginyll-L-phénylalanyl-glycyl-L-alanyl-L-isoleucyl-L-leucyl-L-séryl-L-séryl-L-thréonyl-L-asparaginyll-L-valyl-glycyl-L-séryl-L-asparaginyll-L-thréonyl-L-tyrosinamide

amlintida

(2→7)-disulfuro cíclico de L-lisil-L-cisteinil-L-asparaginil-L-treonil-L-alanil-L-treonil-L-cisteinil-L-alanil-L-treonil-L-glutaminil-L-arginil-L-leucil-L-alanil-L-asparaginil-L-fenilalanil-L-leucil-L-valil-L-histidil-L-seril-L-seril-L-asparaginil-L-asparaginil-L-fenilalanilglicil-L-alanil-L-isoleucil-L-leucil-L-seril-L-seril-L-treonil-L-asparaginil-L-valilglicil-L-seril-L-asparaginil-L-treonil-L-tirosinamida

C₁₆₅H₂₆₁N₅₁O₅₅S₂

Lys – Cys – Asn – Thr – Ala – Thr – Cys – Ala – Thr – Gln – Arg – Leu – Ala –
 Asn – Phe – Leu – Val – His – Ser – Ser – Asn – Asn – Phe – Gly – Ala – Ile –
 Leu – Ser – Ser – Thr – Asn – Val – Gly – Ser – Asn – Thr – Tyr – NH₂

avitriptanum

avitriptan


3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-*N*-methylindole-5-methanesulfonamide

avitriptan

[3-[3-[4-(5-méthoxypyrimidin-4-yl)]pipérazin-1-yl]propyl]-1-*H*-indol-5-yl]-*N*-méthylméthanesulfonamide

avitriptán

3-[3-[4-(5-metoxi-4-pirimidinil)-1-piperazinil]propil]-*N*-metilindol-5-metanosulfonamida

C₂₂H₃₀N₆O₃S

bamaquimastum


bamaquimast

bamaquimast

bamaquimast

3-(3-hydroxypropyl)-1-propyl-2(1*H*)-quinoxalinone methylcarbamate (ester)

méthylcarbamate de 3-(3-oxo-4-propyl-3,4-dihydroquinoxalin-2-yl)propyle

metilcarbamato(éster) de 3-(3-hidroxipropil)-1-propil-2(1*H*)-quinoxalinona $C_{16}H_{21}N_3O_3$ **basiliximabum**

basiliximab

immunoglobulin G 1 (human-mouse monoclonal CH1621 heavy chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal CH1621 light chain, dimer

basiliximab

immunoglobuline G 1 (chaîne lourde de l'anticorps monoclonal chimérique homme-souris CH1621 dirigé contre le récepteur humain de l'interleukine 2), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal chimérique homme-souris CH1621

basiliximab


inmunoglobulina G 1 (cadena pesada del anticuerpo monoclonal quimérico hombre-ratón CH1621 dirigido contra el receptor humano de la interleukina 2), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal quimérico hombre-ratón CH1621

betadexum

betadex

bétadex

betadex

 β -cyclodextrin β -cyclodextrine β -ciclodextrina $C_{42}H_{70}O_{35}$ 

bimoclomolum


bimoclomol

(±)-*N*-(2-hydroxy-3-piperidinopropoxy)nicotinimidoyl chloride

bimoclomol

chlorure de *N*-[(2*RS*)-2-hydroxy-3-(pipéridin-1-yl)propoxy]pyridin-3-carboximidoyl

bimoclomol

cloruro de (±)-*N*-(2-hidroxi-3-piperidinopropoxi)nicotinimidoil $C_{14}H_{20}ClN_3O_2$ **blonanserinum**


blonanserín

2-(4-ethyl-1-piperazinyl)-4-(*p*-fluorophenyl)-5,6,7,8,9,10-hexahydrocyclo-octa[*b*]pyridine

blonansérine

2-(4-éthylpipérazin-1-yl)-4-(4-fluorophényl)-5,6,7,8,9,10-hexahydrocyclo-octa[*b*]pyridine

blonanserina

2-(4-etil-1-piperazinil)-4-(*p*-fluorofenil)-5,6,7,8,9,10-hexahidrocielo-octa[*b*]piridina $C_{23}H_{30}FN_3$ **brasofensinum**


brasofensine

3β-(3,4-dichlorophenyl)-1αH,5αH-tropane-2α-carboxaldehyde (*E*)-(O-methyloxime)

brasofensine

(1*R*,2*R*,3*S*,5*S*)-3-(3,4-dichlorophényl)-8-méthyl-8-azabicyclo[3.2.1]octane-2-carbaldéhyde (*E*)-*O*-méthyloxime

brasofensina

3β-(3,4-diclorofenil)-1αH,5αH-tropano-2α-carboxaldehído (*E*)-(O-metiloxima) $C_{16}H_{20}Cl_2N_2O$ 

brinzolamidum


brinzolamide

(7*F*)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2*H*-thieno[3,2-*e*]-1,2-thiazine-6-sulfonamide 1,1-dioxide

brinzolamide

(4*F*)-4-(éthylamino)-2-(3-méthoxypropyl)-3,4-dihydro-2*H*-thiéno[3,2-*e*]-1,2-thiazine-6-sulfonamide 1,1-dioxyde

brinzolamida

(7*F*)-4-(etilamino)-3,4-dihidro-2-(3-metoxipropil)-2*H*-tieno[3,2-*e*]-1,2-tiazina-6-sulfonamida 1,1-dióxido $C_{12}H_{21}N_3O_5S_3$ **cevimelinum**


cevimeline

(±)-*cis*-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine]

céviméline

(3*RS*,2'*RS*)-2'-méthylspiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane]

cevimelina

(±)-*cis*-2-metilespiro[1,3-oxatiolano-5,3'-quinuclidina] $C_{10}H_{17}NOS$ and enantiomer
et l'énantiomère
y enantiómero**cizolirtinum**

cizolirtine


(±)-5-[α-[2-(dimethylamino)ethoxy]benzyl]-1-methylpyrazole

cizolirtine

N,N-diméthyl-2-[(*RS*)-(1-méthyl-1*H*-pyrazol-5-yl)phénylméthoxy]éthanamine

cizolirtina

(±)-5-[α-[2-(dimetilamino)etoxi]bencil]-1-metilpirazol

 $C_{15}H_{21}N_3O$ and enantiomer
et l'énantiomère
y enantiómero

dalcotidinum


dalcotidine

1-ethyl-3-[3-[(α -piperidino-*m*-tolyl)oxy]propyl]urea

dalcotidine

1-éthyl-3-[3-[(pipéridin-1-yl)méthyl]phénoxy]propyl]urée

dalcotidina

1-etil-3-[3-[(α -piperidino-*m*-tolil)oxi]propil]ureaC₁₉H₂₉N₃O₂**daniplestim**

daniplestim

14-L-alanine-18-L-isoleucine-25-L-histidine-29-L-arginine-32-L-asparagine-37-L-proline-42-L-serine-45-L-methionine-51-L-arginine-55-L-threonine-59-L-leucine-62-L-valine-67-L-histidine-69-L-glutamic acid-73-glycine-76-L-alanine-79-L-arginine-82-L-glutamine-87-L-serine-93-L-serine-98-L-isoleucine-101-L-alanine-105-L-glutamine-109-L-glutamic acid-116-L-valine-120-L-glutamine-123-L-glutamic acid-14-125-interleukin 3 (human clone D11 reduced)

daniplestim

[14-L-alanine-18-L-isoleucine-25-L-histidine-29-L-arginine-32-L-asparagine-37-L-proline-42-L-sérine-45-L-méthionine-51-L-arginine-55-L-thréonine-59-L-leucine-62-L-valine-67-L-histidine-69-acide L-glutamique-73-glycine-76-L-alanine-79-L-arginine-82-L-glutamine-87-L-sérine-93-L-sérine-98-L-isoleucine-101-L-alanine-105-L-glutamine-109-acide L-glutamique-116-L-valine-120-L-glutamine-123-acide L-glutamique]-14-125-interleukin 3 (clone humain D11 précurseur de la partie protéique réduite)

daniplestim

[14-L-alanina-18-L-isoleucina-25-L-histidina-29-L-arginina-32-L-asparagina-37-L-prolina-42-L-sérina-45-L-metionina-51-L-arginina-55-L-treonina-59-L-leucine-62-L-valina-67-L-histidina-69-ácido L-glutámico-73-glicina-76-L-alanina-79-L-arginina-82-L-glutamina-87-L-serina-93-L-serina-98-L-isoleucina-101-L-alanina-105-L-glutamina-109-ácido L-glutámico-116-L-valina-120-L-glutamina-123-ácido L-glutámico]-14-125-interleuquina 3 (clon humano D11 precursor de la fracción proteica reducida)

C₅₆₄H₉₀₉N₁₆₁O₁₆₆S₅

```

ANCSIMIDEI  IHHLKRPPNP  LLDPNNLNSE  DMDILMERNL
RTPNLLAFVR  AVKHLENASG  IEAILRNLQP  CLPSATAAPS
RHPIIIKAGD  WQEFREKLTF  YLVTLEQAQE  QQ

```

dexefaroxanum

dexefaroxan


(+)-(*R*)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline

dexéfaroxan

(+) -2-[(2*R*)-2-éthyl-2,3-dihydrobenzofuran-2-yl]-4,5-dihydro-1*H*-imidazole

dexefaroxán

(+)-(*R*)-2-(2-etil-2,3-dihidro-2-benzofuranil)-2-imidazolina

$C_{13}H_{15}N_2O$ **elacridarum**


elacridar

4'-[2-(3,4-dihydro-6,7-dimethoxy-2(1*H*)-isoquinolyl)ethyl]-5-methoxy-9-oxo-4-acridancarboxanilide

élacridar

N-[4-[2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-2(1*H*)-yl)éthyl]phényl]-5-méthoxy-9-oxo-9,10-dihydroacridine-4-carboxamide

elacridar

4'-[2-(3,4-dihidro-6,7-dimetoxi-2(1*H*)-isoquinolil)etil]-5-metoxi-9-oxo-4-acridancarboxanilida $C_{34}H_{33}N_3O_5$ **eldacimibum**


eldacimibe

cyclic isopropylidene [(3,5-di-*tert*-butyl-4-hydroxyanilino)[hexyl=(*p*-neopentylbenzyl)amino]methylene]malonate

eldacimibe

5-[[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]amino][[4-(2,2-diméthylpropyl)benzyl]hexylamino]méthylène]-2,2-diméthyl-1,3-dioxane-4,6-dione

eldacimiba

[(3,5-di-*tert*-butyl-4-hidroxianilino)[hexil(*p*-neopentilbencil)amino]=metileno]malonato cíclico de isopropilideno $C_{39}H_{53}N_2O_5$ 

eperezolidum

eperezolid


N-[[[(*S*)-3-[3-fluoro-4-(4-glycoloyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

épérezolide

N-[[[(*S*)-3-[3-fluoro-4-[4-(2-hydroxyacétyl)pipérazin-1-yl]phényl]-2-oxooxazolidin-5-yl]méthyl]acétamide

eperezolida

N-[[[(*S*)-3-[3-fluoro-4-(4-glicoloi-1-piperazinil)fenil]-2-oxo-5-oxazolidinil]metil]acetamida

C₁₈H₂₃FN₄O₅**esatenololum**

esatenolol


2-[*p*-[(2*S*)-2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide

ésaténolol

2-[4-[(2*S*)-2-hydroxy-3-[(1-méthyléthyl)amino]propoxy]phényl]acétamide

esatenolol

2-[*p*-[(2*S*)-2-hidroxi-3-(isopropilamino)propoxi]fenil]acetamida

C₁₄H₂₂N₂O₃**faralimomabum**

faralimomab

immunoglobulin G 1 (mouse monoclonal 64G12 γ 1-chain anti-human interferon receptor), disulfide with mouse monoclonal 64G12 light chain, dimer

faralimomab

immunoglobuline G 1 (chaîne γ 1 de l'anticorps monoclonal de souris (64G12) dirigé contre le récepteur humain des interférons de type I), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 64G12

faralimomab

inmunoglobulina G 1 (cadena γ 1 del anticuerpo monoclonal de ratón (64G12) dirigido contra el receptor humano de los interferones de tipo I), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón 64G12

gacyclidinum


gacyclidine

1-[*cis*-2-methyl-1-(2-thienyl)cyclohexyl]piperidine

gacyclidine

1-[(1*RS*,2*SR*)-2-méthyl-1-(thiophén-2-yl)cyclohexyl]pipéridine

gaciclidina

1-[*cis*-2-metil-1-(2-tienil)ciclohexil]piperidina $C_{16}H_{25}NS$ **ganaxolonum**


ganaxolone

3 α -hydroxy-3-methyl-5 α -pregnan-20-one

ganaxolone

3 α -hydroxy-3-méthyl-5 α -prégnan-20-one

ganaxolona

3 α -hidroxi-3-metil-5 α -pregnan-20-ona $C_{22}H_{36}O_2$ **hemoglobinum crosfumarilum**


hemoglobin crosfumaril

hemoglobin A₀ (human $\alpha_2\beta_2$ tetrameric subunit), α -chain 99,99'-diamide with fumaric acid

hémoglobine crosfumaril

99,99'-diamide de la chaîne α de l'hémoglobine A₀ (sous-unité tétramérique $\alpha_2\beta_2$ humaine) avec l'acide fumarique

hemoglobina crosfumarilo

99,99'-diamida de la cadena α de la hemoglobina A₀ (subunidad tetramérica $\alpha_2\beta_2$ humana), con el ácido fumánico

indisetrinum


indisetrón

N-(3,9-dimethyl-*endo*-3,9-diazabicyclo[3.3.1]non-7-yl)-1*H*-indazole-3-carboxamide

indisétron

N-[(1*R*,5*S*,7*S*)-3,9-diméthyl-3,9-diazabicyclo[3.3.1]non-7-yl]-1*H*-indazole-3-carboxamide

indisetrón

N-(3,9-dimetil-*endo*-3,9-diazabicclo[3.3.1]non-7-il)-1*H*-indazol-3-carboxamida
C₁₇H₂₃N₅O**insulinum aspartum**


insulin aspart

28^B-L-aspartic acid-insulin (human)

insuline asparte

[28^B-acide L-aspartique]insuline humaine

insulina asparta

28^B-L-ácido aspártico-insulina(humana)C₂₅₆H₃₈₁N₆₅O₇₉S₆**insulinum glarginum**


insulin glargine


21^A-glycine-30^{Ba}-L-arginine-30^{Bb}-L-arginineinsulin (human)

insuline glargine

[21^A-glycine]30^{Ba}-L-arginine-30^{Bb}-L-arginine-insuline humaine

insulina glargina

21^A-glicina-30^{Ba}-L-arginina-30^{Bb}-L-argininainsulina (humana)C₂₆₇H₄₀₄N₇₂O₇₈S₆

iometopanum (¹²³I)iometopane (¹²³I)methyl 3β-(*p*-[¹²³I]iodophenyl)-1αH,5αH-tropane-2β-carboxylateiométopane (¹²³I)(1*R*,2*S*,3*S*,5*S*)-3-(4-[¹²³I]iodophényl)-8-méthyl-8-azabicyclo[3.2.1]octane-2-carboxylate de méthyleiometopano (¹²³I)3β-(*p*-[¹²³I]iodofenil)-1αH,5αH-tropano-2β-carboxilato de metiloC₁₆H₂₀¹²³INO₂**israpafantum**


israpafant

(±)-4-(*o*-chlorophenyl)-2-(*p*-isobutylphenethyl)-6,9-dimethyl-6*H*-thieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepine

israpafant

(6*RS*)-4-(2-chlorophényl)-6,9-diméthyl-2-[2-[4-(2-méthylpropyl)phényl]éthyl]-6*H*-thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépine

israpafant

(±)-4-(*o*-chlorofenil)-2-(*p*-isobutilfenetil)-6,9-dimetil-6*H*-thieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepinaC₂₈H₂₉ClN₄Sand enantiomer
et énantiomère
y enantiómero**keliximabum**

keliximab

immunoglobulin G 1 (human-Macaca monoclonal CE9.1 γ1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9 1 κ-chain, dimer

kéliximab

immunoglobuline G 1 (chaîne γ1 de l'anticorps monoclonal chimérique homme-macaque CE9 1 dirigé contre l'antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-macaque CE9.1

keliximab

inmunoglobulina G 1 (cadena γ1 del anticuerpo monoclonal quimérico hombre-macaco CE9.1 dirigido contra el antígeno CD4 humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal dímérico hombre-macaco CE9.1

lanoteplasum

lanoteplase

N-[*N*²-(*N*-glycyl-L-alanyl)-L-arginyl]-117-L-glutamine-245-L-methionine-(1-5)-(87-527)-plasminogen activator (human tissue-type protein moiety)

lanotéplase

N-[*N*²-(*N*-glycyl-L-alanyl)-L-arginyl]-[117-L-glutamine-245-L-méthionine]- (1-5)-(87-527)- activateur du plasminogène (type tissulaire humain, partie protéique)

lanoteplasa

N-[*N*²-(*N*-glicil-L-alanil)-L-arginil]-[117-L-glutamina-245-L-metionina]- (1-5)-(87-527)-activador del plasminógeno (tipo tisular humano, fracción proteica)

C₂₁₈₄H₃₃₂₃N₆₃₃O₆₆₆S₂₉

GARSYQVIDT	RATCYEDQGI	SYRGTWSTAE	SGAECTNWQS
SALAQKPYSG	RRPDAIRLGL	GNHNYCRNPD	RDSKPWCYVF
KAGKYSSEFC	STPACSEGN	DCYFGNGSAY	RGTHSLTESG
ASCLFWNSMI	LIGKVYTAQN	PSAQALGLGK	HNYCRNPDGD
AKPWCHNLKN	RRLTWEYCDV	PSCSTCGLRQ	YSQPQFRIKG
GLFADIASHP	WQAAIFAKHR	RSPGERFLCG	GILISSCWIL
SAAHCFQERF	PPHHLTVILG	RTYRVVPGE	EQKFEVEKYI
VHKEFDDDTY	DNDIALQLK	SDSSRCAQES	SVVRTVCLPP
ADLQLPDWTE	CELSGYGKHE	ALSPFYSERL	KEAHVRLYPS
SRCTSQHLLN	RTVTDNMLCA	GDTRSGGPQA	NLHDACQGDS
GGPLVCLNDG	RMTLVGIISW	GLGCGQKDVP	GVYTKVTNYL
DWIRDNMRP			

* binding sites of sugar chain

* sites de fixation de la chaîne osidique

* lugares de union de la cadena osidica

lasinavirum

lasinavir


tert-butyl [(α S)- α -[(1*S*,3*R*)-1-hydroxy-3-[[[(1*S*)-1-[(2-methoxyethyl)carbamoyl]-2-methylpropyl]carbamoyl]-4-(2,3,4-trimethoxyphenyl)butyl]phenethyl]=carbamate

lasinavir

[(1*S*,2*S*,4*R*)-1-benzyl-2-hydroxy-5-[[[(1*S*)-1-[(2-méthoxyéthyl)carbamoyl]-2-méthylpropyl]amino]-5-oxo-4-(2,3,4-triméthoxybenzyl)pentyl]carbamate de 1,1-diméthyléthyle

lasinavir

[(α S)- α -[(1*S*,3*R*)-1-hidroxi-3-[[[(1*S*)-1-[(2-metoxietil)-carbamoiil]-2-metilpropil]carbamoiil]-4-(2,3,4-trimetoxifenil)butil]fenetil]carbamato de *tert*-butilo

$C_{35}H_{53}N_3O_9$ **ledoxantrone**


ledoxantrone

5-[(2-aminoethyl)amino]-2-[2-(diethylamino)ethyl]-2*H*-[1]benzothiopyrano=[4,3,2-*cd*]indazol-8-ol

ledoxantrone

5-[(2-aminoéthyl)amino]-2-[2-(diéthylamino)éthyl]-2*H*-[1]benzothiopyrano=[4,3,2-*cd*]indazol-8-ol

ledoxantrona

5-[(2-aminoetil)amino]-2-[2-(dietilamino)etil]-2*H*-[1]benzotiopirano=[4,3,2-*cd*]indazol-8-ol $C_{21}H_{27}N_5OS$ **linezolidum**


linezolid

N-[[(*S*)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide

linézolide

N-[[(5*S*)-3-[3-fluoro-4-(morpholin-4-yl)phényl]-2-oxooxazolidin-5-yl]méthyl]acétamide

linezolid

N-[[(*S*)-3-(3-fluoro-4-morfolinofenil)-2-oxo-5-oxazolidinil]metil]acetamida $C_{16}H_{20}FN_3O_4$ 

lintuzumabum

lintuzumab

immunoglobulin G 1 (human-mouse monoclonal HuM195 γ 1-chain anti-human antigen CD 33), disulfide with human monoclonal HuM195 κ -chain, dimer

lintuzumab

immunoglobuline G 1 (chaîne légère γ 1 de l'anticorps monoclonal de souris humanisé HuM195 dirigé contre l'antigène CD 33 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain HuM195

lintuzumab

inmunoglobulina G 1 (cadena ligera γ 1 del anticuerpo monoclonal de ratón humanizado HuM195 dirigido contra el antígeno CD 33 humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humano Hu195**metesindum**


metesind

4-[[α -[(2-aminobenz[*cd*]indol-6-yl)methylamino]-*p*-tolyl]sulfonyl]morpholine

métésind

4-[[4-[[[(2-aminobenz[*cd*]indol-6-yl)(méthyl)amino]méthyl]phényl]=sulfonyl]morpholine

metesind

4-[[α -[(2-aminobenz[*cd*]indol-6-il)metilamino]-*p*-tolil]sulfonil]morfolinaC₂₃H₂₄N₄O₃S**milfasartanum**


milfasartan

methyl 2-[[4-butyl-2-methyl-6-oxo-5-[*p*-(α -1*H*-tetrazol-5-yl)phenyl]benzyl]-1(6*H*)-pyrimidinyl]methyl]-3-thiophenecarboxylate

milfasartan

2-[[4-butyl-2-méthyl-6-oxo-5-[4-[2-(1*H*-tétrazol-5-yl)phényl]bénzyl]pyrimidin-1(6*H*)-yl]méthyl]thiophène-3-carboxylate de méthyle

milfasartán

2-[[4-butil-2-metil-6-oxo-5-[*p*-(α -1*H*-tetrazol-5-ilfenil)bencil]-1(6*H*)-pirimidinil]metil]-3-tiofenocarboxilato de metiloC₃₀H₃₀N₆O₃S

minalrestatum


minalrestat

(±)-2-(4-bromo-2-fluorobenzyl)-6-fluorospiro[isoquinoline-4(1*H*),3'-pyrrolidine]-1,2',3,5'(2*H*)-tetrone

minalrestat

(3'*RS*)-2-(4-bromo-2-fluorobenzyl)-6-fluorospiro[isoquinoléine-4(1*H*),3'-pyrrolidine]-1,2',3,5'(2*H*)-tétrone

minalrestat

(±)-2-(4-bromo-2-fluorobencil)-6-fluoroespiro[isoquinolina-4(1*H*),3'-pirrolidin]-1,2',3,5'(2*H*)-tetronaC₁₉H₁₁BrF₂N₂O₄**nagrestipenum**

nagrestipen


26-L-alaninelymphokine MIP 1α (human clone pAT464 macrophage inflammatory)

nagrestipen

[26-L-alanine]lymphokine MIP 1α (clone pAT464 de macrophage inflammatoire humain)

nagrestipen

[26-L-alanina]infoquina MIP 1α (clon pAT464 de macrófago inflamatorio humano)

C₃₃₈H₅₁₆N₈₈O₁₀₈S₄**nelfinavirum**

nelfinavir



(3*S*,4*aS*,8*aS*)-*N*-*tert*-butyl-2-[(2*R*,3*R*)-3-(3,2-cresotamido)-2-hydroxy-4-(phenylthio)butyl]decahydro-3-isoquinolinecarboxamide

nelfinavir

(3*S*,4*aS*,8*aS*)-*N*-(1,1-diméthyléthyl)-2-[(2*R*,3*R*)-2-hydroxy-3-[(3-hydroxy-2-méthylbenzoyl)amino]-4-(phénylsulfanyl)butyl]décahydroisoquinoléine-3-carboxamide

nelfinavir

(3*S*,4*aS*,8*aS*)-*N*-*terc*-butil-2-[(2*R*,3*R*)-3-(3,2-cresotamido)-2-hidroxi-4-feniltio]butil]decahidro-3-isoquinolinacarboxamida

**nerelimomabum**

nerelimomab

immunoglobulin G 1 (mouse monoclonal BAYX1351 γ 1-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal BAYX1351 light chain, dimer

nérélimomab

immunoglobuline G 1 (chaîne γ 1 de l'anticorps monoclonal de souris BAYX1351 dirigé contre le facteur de nécrose tumorale α humain), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris BAYX1351

nerelimomab

inmunoglobulina G 1 (cadena ligera mouse monoclonal BAYX1351 γ 1-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal BAYX1351 light chain, dimer

omiloxetinum

omiloxetine



4'-fluoro-2-[(*trans*-4-(*p*-fluorophenyl)-3-[[3,4-(methylenedioxy)=phenoxy]methyl]piperidino]acetophenone

omiloxétine

2-[(*(3RS,4SR)*-3-[(1,3-benzodioxol-5-yloxy)méthyl]-4-(4-fluorophényl)=pipéridin-1-yl]-1-(4-fluorophényl)éthanone

omiloxetino

4'-fluoro-2-[(*trans*-4-(*p*-fluorofenil)-3-[[3,4-(metilenodioxi)=fenoxi]metil]piperidino]acetofenona



and enantiomer
et l'énantiomère
y enantiómero

opratonii iodidum

opratonium iodide


iodure d'opratonium

ioduro de opratonio

trimethyl[3-(undecenamido)propyl]ammonium iodide

iodure de *N,N,N*-triméthyl-3-(undéc-10-énoylamino)propan-1-aminium

ioduro de trimetil[3-(undecenamido)propil]amonio

 $C_{17}H_{35}IN_2O$ **oprelvekinum**

oprelvekin

oprelvékine

oprelvekina

2-178-interleukin 11 (human clone pXM/IL-11)

2-178-interleukine 11 (clone humain pXM/IL-11)

2-178-interleuquina 11 (clon humano pXM/IL-11)

 $C_{854}H_{1411}N_{253}O_{235}S_2$

GPPPGPPRVS PDPRAELDST VLLTRSLLD TRQLAAQLR
 KFPADGDHNL DSLPTLAMS GALGALQLPG VLTRLRADL
 SYLRHVQWLR RAGGSSSLKTL EPELGTQLQAR LDRLLRRLQ
 LMSRLALEPQP PPDPPAPPLA PPSSAWGGIR AAHAITLGL
 LTLDWAVRGL LLLKTRL

osutidinum

osutidine


osutidine

osutidina

(±)-*N*-[(*E*)-[(*p*,*β*-dihydroxyphenethyl)amino][[2-[[5-[(methylamino)=methyl]furfuryl]thio]ethyl]amino]methylene]methanesulfonamide

(*E*)-1-[(2*RS*)-2-hydroxy-2-(4-hydroxyphényl)éthyl]-3-[2-[[[5-[(méthylamino)=méthyl]-2-furyl]méthyl]sulfanyl]éthyl]-2-(méthylsulfonyl)guanidine

(±)-*N*-[(*E*)-[(*p*,*β*-dihidroxiifenetil)amino][[2-[[5-[(metilamino)=metil]furfuri]tio]etil]amino]metileno]metanosulfonamida

 $C_{19}H_{28}N_4O_5S_2$ 


and enantiomer
et l'énantiomère
y enantiómero

pelubiprofenum

pelubiprofen

pélubiprofène


pelubiprofeno

(±)-*p*-[[(*E*)-2-oxocyclohexylidene]methyl]hydrotropic acidacide (2*RS*)-2-[4-[(*E*)-(2-oxocyclohexylidène)méthyl]phényl]propanoïqueácido(±)-*p*-[[(*E*)-2-oxociclohexiliden]metil]hidratrópicoC₁₆H₁₈O₃**pumaprazolum**

pumaprazole

pumaprazole


pumaprazol

methyl 2-[[[(2,3-dimethylimidazo[1,2-*a*]pyridin-8-yl)amino]methyl]-3-methylcarbanilate2-[[[(2,3-diméthylimidazo[1,2-*a*]pyridin-8-yl)amino]méthyl]-3-méthylphényl]carbamate de méthyle2-[[[(2,3-dimetilimidazo[1,2-*a*]piridin-8-il)amino]metil]-3-metilcarbanilato de metiloC₁₉H₂₂N₄O₂**quilostigminum**

quilostigmine

quilostigmine

quilostigmina

(3*aS*,8*aR*)-1,2,3,3*a*,8,8*a*-hexahydro-1,3*a*,8-trimethylpyrrolo[2,3-*b*]indol-5-yl 3,4-dihydro-2(1*H*)-isoquinolinecarboxylate3,4-dihydroisoquinoléine-2(1*H*)-carboxylate de (3*aS*,8*aR*)-1,3*a*,8-triméthyl-1,2,3,3*a*,8,8*a*-hexahydropyrrolo[2,3-*b*]indol-5-yle3,4-dihidro-2(1*H*)-isoquinolinacarboxilato de (3*aS*,8*aR*)-1,2,3,3*a*,8,8*a*-hexahidro-1,3*a*,8-trimetilpirrolo[2,3-*b*]indol-5-iloC₂₃H₂₇N₃O₂

retigabinum


retigabine

ethyl 2-amino-4-[(*p*-fluorobenzyl)amino]carbanilate

rétigabine

[2-amino-4-[(4-fluorobenzyl)amino]phényl]carbamate d'éthyle

retigabina

2-amino-4-[(*p*-fluorobencil)amino]carbanilato de etiloC₁₆H₁₈FN₃O₂**sabcomelinum**


sabcomeline

(*R*)-3-quinuclidineglyoxylonitrile (*Z*)-(O)-methyloxime

sabcoméline

(*Z*)-2-[(3*R*)-1-azabicyclo[2.2.2]oct-3-yl]-2-(méthoxyimino)acétonitrile

sabcomelina

(*R*)-3-quinuclidinagloxilonitrilo (*Z*)-(O)-metiloximaC₁₀H₁₅N₃O**scopinastum**


scopinast


7-[3-[4-[bis(*p*-fluorophenyl)hydroxymethyl]piperidino]propoxy]-6-methoxycoumarin

scopinast

7-[3-[4-[bis(4-fluorophényl)hydroxyméthyl]pipéridin-1-yl]propoxy]-6-méthoxy-2*H*-chromén-2-one

escopinast

7-[3-[4-[bis(*p*-fluorofenil)hidroximetil]piperidino]propoxi]-6-metoxicumarinaC₃₁H₃₁F₂NO₅

soretolidumsoretolide 2,6-dimethyl-*N*-(5-methyl-3-isoxazolyl)benzamidesorétolide 2,6-diméthyl-*N*-(5-méthylisoxazol-3-yl)benzamidesoretolida 2,6-dimetil-*N*-(5-metil-3-isoxazolil)benzamidaC₁₃H₁₄N₂O₂**tasonerminum**

tasonermin 1-157-tumor necrosis factor alfa-1a (human)

tasonermine 1-157-facteur de nécrose tumorale humain alfa-1a

tasonermina 1-157-factor de necrosis tumoral alfa-1a (humano)

C₇₇₈H₁₂₂₅N₂₁₅O₂₃₁S₂

VRSSSRTPSD KPAHVAVANP QAEGQLQWLN RRANALLAN
 VELRDNQLVV PSEGLYLIYS QVLFGQGQCP STHVLLTHT
 SRIAVSYQTK VNLLSAIKSP CQRETPEGAE AKPWYEPIY
 GGVFQLEKGD RLsAEINRPD YLDFAESGQV YFGIIAL

technetium (^{99m}Tc) nofetumomabum**merpentanum**technetium (^{99m}Tc) nofetumomab

merpentan

immunoglobulin G 2b (mouse monoclonal NR-LU-10 Fab fragment anti-human tumor), disulfide with mouse monoclonal NR-LU-10 κ-chain, [N,N'-[(2-formylethyl)ethylene]bis[2-mercaptoacetamidato]](4-)-N,N',S,S']oxo=[^{99m}Tc]technetate(1-) conjugate

technétium (^{99m}Tc) nofétumomab

merpentan

immunoglobuline G 2b (fragment Fab de l'anticorps monoclonal de souris NR-LU-10 dirigé contre une tumeur humaine), disulfure avec la chaîne κ de l'anticorps monoclonal de souris NR-LU-10 conjuguée avec l'oxo-[[N,N'-[1-(3-oxopropyl)éthane-1,2-diyl]bis[2-sulfanylacétamidato]](4-)-N,N',S,S']=[^{99m}Tc]technétate(1-)

tecnecio (^{99m}Tc) nofetumomab

merpentán

inmunoglobulina G 2b (fragmento Fab del anticuerpo monoclonal de ratón NR-LU-10 dirigido contra un tumor humano), disulfuro con la cadena κ del anticuerpo monoclonal de ratón NR-LU-10 conjugado con el oxo-[[N,N'-[1-(3-oxopropil)etano-1,2-diil]bis[2-sulfanilacetamidato]](4-)-N,N',S,S']=[^{99m}Tc]tecnetato(1-)

temiverinum

temiverine


4-(diethylamino)-1,1-dimethyl-2-butylnyl (±)-α-phenylcyclohexaneglycolate

témivérine

(2*RS*)-2-cyclohexyl-2-hydroxy-2-phénylacétate de 4-(diéthylamino)-1,1-diméthylbut-2-ynyle

temiverina

(±)-α-fenilciclohexanoglicolato de 4-(dietilamino)-1,1-dimetil-2-butinilo

C₂₄H₃₅NO₃**ticolubantum**

ticolubant


(E)-6-[[[(2,6-dichlorophenyl)thio]methyl]-3-(phenethoxy)-2-pyridineacrylic acid

ticolubant

acide (E)-3-[6-[[[(2,6-dichlorophényl)sulfanyl]méthyl]-3-(2-phényléthoxy)=pyridin-2-yl]prop-2-énoïque

ticolubant

ácido (E)-6-[[[(2,6-diclorofenil)tio]metil]-3-(fenetilo)-2-piridinacrílico

C₂₃H₁₉Cl₂NO₃S**valsopodarum**


valsopodar

cyclo[(2*S*,4*R*,6*E*)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl]-L-valyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]

valsopodar

cyclo[L-alanyl-D-alanyl-N-méthyl-L-leucyl-N-méthyl-L-leucyl-N-méthyl-L-valyl-[(2*S*,4*R*,6*E*)-4-méthyl-2-(méthylamino)-3-oxooct-6-énoyl]-L-valyl-N-méthylglycyl-N-méthyl-L-leucyl-L-valyl-N-méthyl-L-leucyl]

valsopodar

ciclo[(2*S*,4*R*,6*E*)-4-metil-2-(metilamino)-3-oxo-6-octenoi]-L-valil-N-metilglicil-N-metil-L-leucil-L-valil-N-metil-L-leucil-L-alanil-D-alanil-N-metil-L-leucil-N-metil-L-leucil-N-metil-L-valil]C₆₃H₁₁₁N₁₁O₁₂

vedaclidinum

vedaclidine


(S)-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]quinuclidine

védaclidine

(3S)-3-[4-(butylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[2.2.2]octane

vedaclidina

(S)-3-[4-(butiltio)-1,2,5-tiadiazol-3-il]quinuclidina

 $C_{13}H_{21}N_3S_2$ 

MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES

Dénominations communes internationales recommandées (DCI Rec.): Liste 30

(Informations pharmaceutiques OMS, Vol. 4, No.3, 1990)

p. 14	saruplasum	<i>remplacer la description par:</i>
	saruplase	pro-urokinase (activateur d'enzyme) (fraction protéique issue du clone humain pUK4/pUK18), non-glycosylée

Dénominations communes internationales recommandées (DCI Rec.): Liste 33

(Informations pharmaceutiques OMS, Vol. 7, No.3, 1993)

p. 6	nasaruplasum	<i>remplacer la description par:</i>
	nasaruplase	pro-urokinase (activateur d'enzyme) (fraction protéique issue du clone humain pA3/pD2/pF1), glycosylée

Pour toutes modifications apportées aux **Dénominations communes internationales recommandées (DCI Rec.): Listes 34-37** voir page 181, section *AMENDMENTS TO PREVIOUS LISTS*.

MODIFICACIONES A LAS LISTAS ANTERIORES

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 30

(Información Farmacéutica, OMS, Vol. 4, No. 3, 1990)

p. 13	saruplasum	<i>sustituyase la descripción por la siguiente:</i>
	saruplase	prouroquinasa (activador de enzima) (fracción proteica procedente del clon humano pUK4/pUK18), no glucosilada

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 33

(Información Farmacéutica, OMS, Vol. 7, No. 3, 1993)

p. 6	nasaruplasum	<i>sustituyase la descripción por la siguiente:</i>
	nasaruplase	prouroquinasa (activador de enzima) (fracción proteica procedente del clon humano pA3/pD2/pF1), glucosilada

Para cualquier modificación de las **Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Listas 34-37** vease página 181, sección *AMENDMENTS TO PREVIOUS LISTS*.

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes impaires des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

